Lilly Prepares For Zyprexa Expiration; Increases R&D Spend
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly's earnings are in line with analyst expectations, but higher costs cut into profits as the company prepares for a revenue decline.